Ca­jal Neu­ro­science launch­es with $96M Se­ries A, tack­ling Alzheimer's and Parkin­son's

Ca­jal Neu­ro­science has emerged with a $96 mil­lion Se­ries A and plans to dis­cov­er drug can­di­dates in Alzheimer’s and Parkin­son’s with a wealth of gene da­ta.

Ca­jal, named af­ter Span­ish neu­ro­sci­en­tist San­ti­a­go Ramón y Ca­jal, was found­ed by Ian Peikon and An­drew Der­van around two years ago out of the Lux Cap­i­tal of­fices in New York City, but the duo quick­ly de­cid­ed to move the com­pa­ny across the US to Seat­tle due to the in­sti­tu­tions in the area hav­ing more neu­ro­science ex­per­tise. Af­ter the move out west, Peikon told End­points News the com­pa­ny quick­ly start­ed look­ing for new tar­gets in neu­rode­gen­er­a­tive dis­eases and has al­so grown to around 55 em­ploy­ees.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN